The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Experts say a weekly injection could make life easier for people who administer insulin on a daily basis. The race between drug manufacturers Novo Nordisk and Eli Lilly to develop a once-weekly ...

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as ...

Amycretin has some intriguing results in obesity Amycretin, an experimental Novo Nordisk obesity pill that ... “Obviously GLP-1, specifically the longer-acting GLP-1s, have changed the field ...

In March 2024, Novo Nordisk announced that the European Medicines ... Story continues Due to its rapid onset and relatively short duration, short-acting insulin is ideal for providing flexibility in ...

Notable short-acting insulin companies such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Torrent Pharmaceuticals Ltd., Gland Pharma, Lupin, Sensile, Zydus Cadila, Cipla, Glenmark ...

Short-acting ... acting insulin market is marked by the presence of major pharmaceutical companies and a continuous stream of new entrants. Established players, such as Novo Nordisk, Sanofi ...

intensifying the company's race with Novo Nordisk to develop longer-acting insulins. Lilly's once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily basal ...